Takeda’s dengue vaccine candidate (TAK-003) is based on a modified strain of dengue virus, which provides the genetic ‘backbone’ for all four vaccine viruses and exposes the individual to a number of components of the virus that could be important in protection against future infection with dengue virus.

Takeda believes that mosquito-borne infectious diseases, including dengue, are critical threats to public health and is working on a vaccine candidate to help reduce disease burden.

TAK-003 is currently in the pivotal Phase 3 TIDES trial in dengue-endemic Latin American and Asian Countries. TIDES is Takeda’s largest clinical trial to date.

20,100 healthy children and adolescents were enrolled in the trial from eight dengue endemic countries in Latin America (Brazil, Colombia, Panama, Dominican Republic, Nicaragua) and Asia Pacific (Philippines, Thailand, Sri Lanka). These are areas where there are unmet needs in dengue prevention and where severe dengue is the leading cause of serious illness and death among children.

The double-blind, randomized and placebo-controlled Phase 3 trial is investigating the safety and efficacy of a two dose regimen of TAK-003, administered three months apart, to protect children and adolescents against all four strains of dengue virus, regardless of previous dengue exposure.

Takeda is working to secure the necessary evidence from clinical trials to support the use of its dengue vaccine candidate in people who need it, including healthy children and adults in dengue endemic and non-endemic countries.

Reference